InsiderTrades

Form 4 for LAB STANDARD BIOTOOLS INC.

Accepted 2025-04-08 00:00:00 ET · period of report 2025-04-04 · accession 0000950170-25-052047 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-04-08 2025-04-04 LAB Egholm Michael Pres, CEO, Dir M - OptEx $0.00 +196.5K 2.83M +7% $0
D 2025-04-08 2025-04-04 LAB Egholm Michael Pres, CEO, Dir F - Tax $1.07 -57.7K 2.77M -2% -$61.7K
D 2025-04-08 2025-04-04 LAB Egholm Michael Pres, CEO, Dir M - OptEx $0.00 -196.5K 196.5K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-04-04 M A 196,512 $0.00 2,832,518 D — —
2 Common Common Stock 2025-04-04 F D 57,676 $1.07 2,774,842 D — — (F1) The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.
3 Derivative Restricted Stock Units 2025-04-04 M D 196,512 $0.00 196,513 D — · — to — 196,512 Common Stock (F2) Each RSU represents the contingent right to receive one share of the Issuer's common stock. (F3) On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.